Cognition Therapeutics Study Shows Zervimesine Slows DLB Progression
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Cognition Therapeutics presented an analysis from the Phase 2 COG1201 SHIMMER study of zervimesine in dementia with Lewy bodies, or DLB, at the AD/PD 2026 Alzheimer's & Parkinson's Diseases Conference. The analysis focuses on Zervimesine's treatment effects on the behavioral and psychiatric symptoms most commonly associated with DLB. Zervimesine treatment resulted in an 86% slowing of decline on NPI-12 vs placebo in that Phase 2 study. This slowing of decline reflects zervimesine's disease-modifying mechanism of action. Cognition believes zervimesine has the potential to slow DLB progression and reduce the progression of its associated neuropsychiatric symptoms. Its unique mechanism should also allow zervimesine to be used in DLB patients who cannot tolerate traditional antipsychotics and benzodiazepines. Unlike traditional antipsychotics, zervimesine demonstrated a directionally favorable impact on cognitive fluctuations, memory, movement symptoms, and activities of daily living.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CGTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CGTX
Wall Street analysts forecast CGTX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.180
Low
3.00
Averages
3.00
High
3.00
Current: 1.180
Low
3.00
Averages
3.00
High
3.00
About CGTX
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812 and pipeline of sigma-2 modulators can regulate pathways that are impaired in these diseases for the treatment of degenerative diseases. Its lead product candidate, CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins. Its pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways. It is developing other product candidates in the area of synucleinopathies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cognition Therapeutics CEO to Present at Financial Conferences
- CEO Conference Presentation: Cognition Therapeutics' CEO Lisa Ricciardi is set to present at the Jefferies Global Healthcare Conference on June 4, 2026, where she will provide updates on the company's registration program for DLB psychosis, enhancing investor confidence in the company's future prospects.
- Webcast Availability: Ricciardi's presentations will be available via live and archived webcasts on the company's Investor Relations website, ensuring that a broad audience of investors and stakeholders can access critical information, thereby improving the company's transparency and market awareness.
- Clinical Research Progress: Cognition Therapeutics is advancing its lead candidate zervimesine (CT1812) in clinical trials, which has shown promising tolerability and efficacy signals in patients with DLB and mild-to-moderate Alzheimer's disease, potentially opening new market opportunities for the company.
- Funding Support Background: The company has secured nearly $200 million in grants from the National Institutes of Health and related foundations to support its research in neurodegenerative diseases, underscoring its leadership position and ongoing innovation capabilities in the industry.
See More
Cognition Therapeutics Discusses Positive Path Forward with FDA for Zervimesine Registration
- FDA Meeting Outcomes: Cognition Therapeutics held a meeting with the FDA on May 20, 2026, to discuss results from the Phase 2 study of zervimesine (CT1812) in dementia with Lewy bodies (DLB) patients, indicating positive progress in advancing the registration study and potentially offering new treatment options for patients.
- Strong Clinical Signals: Based on robust efficacy signals from the Phase 2 SHIMMER study, Cognition plans to advance zervimesine into late-stage clinical trials targeting DLB psychosis patients, which could significantly enhance patient quality of life and alleviate caregiver burdens.
- Funding Support Background: Cognition has secured nearly $200 million in grants from the National Institutes of Health and related foundations to support its clinical research in neurodegenerative diseases, demonstrating the company's strong capabilities and market confidence in R&D.
- Future Outlook: Cognition anticipates receiving formal minutes from the FDA in June, which will further clarify the registration plans for zervimesine, marking a strategic positioning and market potential in the treatment of neurodegenerative diseases.
See More
Cognition Therapeutics Secures New Donation to Extend EAP for DLB Patients
- Donation Extends EAP: Cognition Therapeutics has received a donation from Jeffrey Pechter, successfully extending the Expanded Access Program (EAP) for dementia with Lewy bodies (DLB) patients, allowing 32 participants to receive two years of treatment, significantly enhancing patient access to potential therapies.
- Drug Development Progress: The EAP provides participants with 100 mg of the investigational drug zervimesine daily, aimed at protecting neuronal function, and is expected to drive further clinical trials based on positive results from the 2025 SHIMMER study.
- FDA Meeting Plans: Cognition plans to meet with the FDA Division of Psychiatry to discuss the registration program for zervimesine in DLB psychosis, which is anticipated to provide crucial guidance for future clinical trials and expedite the drug's path to market.
- Industry Impact: Given the lack of effective treatments for DLB, the successful implementation of this EAP not only offers new hope for patients but also solidifies Cognition's market position in the neurodegenerative disease sector, potentially attracting more investment and attention.
See More
Cognition Therapeutics Q1 Earnings Beat Expectations
- Earnings Performance: Cognition Therapeutics reported a Q1 GAAP EPS of -$0.05, beating expectations by $0.02, indicating improvements in financial management that may boost investor confidence.
- Cash Reserves: As of March 31, 2026, the company had approximately $31.2 million in cash, cash equivalents, and restricted cash, reflecting a healthy liquidity position that supports future operations and investments.
- Grant Funding: The remaining obligated grant funds from the National Institute on Aging total $25.6 million, providing crucial financial support for its R&D activities, potentially accelerating the development of new therapies.
- Operational Outlook: Cognition Therapeutics estimates sufficient cash to fund operations and capital expenditures through the second quarter of 2027, ensuring financial stability that underpins the company's strategic growth plans.
See More
Cognition Therapeutics CEO to Present at Needham Conference
- Conference Presentation: Cognition Therapeutics' CEO Lisa Ricciardi is scheduled to present at the 25th Annual Needham Virtual Healthcare Conference on April 13 at 3:00 PM ET, where she will provide updates on the company's development programs for Alzheimer's disease and dementia with Lewy bodies, likely drawing investor interest.
- Clinical Research Progress: The company's investigational drug CT1812 (zervimesine) has shown promising efficacy signals in Phase 2 trials for dementia with Lewy bodies and mild-to-moderate Alzheimer's disease, with plans to advance it into late-stage clinical trials to address the urgent market need for effective treatments.
- Funding Support Background: Cognition Therapeutics has secured nearly $200 million in grants from the National Institutes of Health and related foundations to support its clinical research in neurodegenerative diseases, highlighting the company's strong R&D capabilities and market potential within the industry.
- Innovative Drug Development: As the company's lead candidate, CT1812 aims to help millions of families by developing novel and accessible therapies, reflecting the company's strategic vision and social responsibility in addressing neurodegenerative diseases.
See More
Cognition Therapeutics Advances CT1812 to Late-Stage Trials for DLB Psychosis
- Clinical Trial Progress: Cognition Therapeutics is advancing zervimesine (CT1812) into late-stage trials for dementia with Lewy bodies (DLB) psychosis, with an $80 million Phase 2 START trial readout expected in the second half of 2027, indicating significant progress in the treatment of neurodegenerative diseases.
- SHIMMER Trial Results: At the International Lewy Body Dementia Conference, zervimesine demonstrated a favorable impact across various symptom domains in the SHIMMER trial, particularly in neuropsychiatric assessments, highlighting its potential in the DLB psychosis market and possibly driving future demand.
- Commitment to Alzheimer's Disease: The Phase 2 SHINE study for mild-to-moderate Alzheimer's disease showed zervimesine achieving cognitive decline reductions comparable to approved monoclonal antibodies, especially in participants with low p-tau217 levels, indicating its therapeutic potential.
- START Study Funding Assurance: The START study has fully enrolled 545 participants with mild cognitive impairment and early Alzheimer's disease, funded by NIH grants, and is expected to provide critical data for the second half of 2027, further advancing zervimesine's clinical development.
See More
Cognition Therapeutics CEO to Present at Financial Conferences
- CEO Conference Presentation: Cognition Therapeutics' CEO Lisa Ricciardi is set to present at the Jefferies Global Healthcare Conference on June 4, 2026, where she will provide updates on the company's registration program for DLB psychosis, enhancing investor confidence in the company's future prospects.
- Webcast Availability: Ricciardi's presentations will be available via live and archived webcasts on the company's Investor Relations website, ensuring that a broad audience of investors and stakeholders can access critical information, thereby improving the company's transparency and market awareness.
- Clinical Research Progress: Cognition Therapeutics is advancing its lead candidate zervimesine (CT1812) in clinical trials, which has shown promising tolerability and efficacy signals in patients with DLB and mild-to-moderate Alzheimer's disease, potentially opening new market opportunities for the company.
- Funding Support Background: The company has secured nearly $200 million in grants from the National Institutes of Health and related foundations to support its research in neurodegenerative diseases, underscoring its leadership position and ongoing innovation capabilities in the industry.
See More
Cognition Therapeutics Discusses Positive Path Forward with FDA for Zervimesine Registration
- FDA Meeting Outcomes: Cognition Therapeutics held a meeting with the FDA on May 20, 2026, to discuss results from the Phase 2 study of zervimesine (CT1812) in dementia with Lewy bodies (DLB) patients, indicating positive progress in advancing the registration study and potentially offering new treatment options for patients.
- Strong Clinical Signals: Based on robust efficacy signals from the Phase 2 SHIMMER study, Cognition plans to advance zervimesine into late-stage clinical trials targeting DLB psychosis patients, which could significantly enhance patient quality of life and alleviate caregiver burdens.
- Funding Support Background: Cognition has secured nearly $200 million in grants from the National Institutes of Health and related foundations to support its clinical research in neurodegenerative diseases, demonstrating the company's strong capabilities and market confidence in R&D.
- Future Outlook: Cognition anticipates receiving formal minutes from the FDA in June, which will further clarify the registration plans for zervimesine, marking a strategic positioning and market potential in the treatment of neurodegenerative diseases.
See More
Cognition Therapeutics Secures New Donation to Extend EAP for DLB Patients
- Donation Extends EAP: Cognition Therapeutics has received a donation from Jeffrey Pechter, successfully extending the Expanded Access Program (EAP) for dementia with Lewy bodies (DLB) patients, allowing 32 participants to receive two years of treatment, significantly enhancing patient access to potential therapies.
- Drug Development Progress: The EAP provides participants with 100 mg of the investigational drug zervimesine daily, aimed at protecting neuronal function, and is expected to drive further clinical trials based on positive results from the 2025 SHIMMER study.
- FDA Meeting Plans: Cognition plans to meet with the FDA Division of Psychiatry to discuss the registration program for zervimesine in DLB psychosis, which is anticipated to provide crucial guidance for future clinical trials and expedite the drug's path to market.
- Industry Impact: Given the lack of effective treatments for DLB, the successful implementation of this EAP not only offers new hope for patients but also solidifies Cognition's market position in the neurodegenerative disease sector, potentially attracting more investment and attention.
See More
Cognition Therapeutics Q1 Earnings Beat Expectations
- Earnings Performance: Cognition Therapeutics reported a Q1 GAAP EPS of -$0.05, beating expectations by $0.02, indicating improvements in financial management that may boost investor confidence.
- Cash Reserves: As of March 31, 2026, the company had approximately $31.2 million in cash, cash equivalents, and restricted cash, reflecting a healthy liquidity position that supports future operations and investments.
- Grant Funding: The remaining obligated grant funds from the National Institute on Aging total $25.6 million, providing crucial financial support for its R&D activities, potentially accelerating the development of new therapies.
- Operational Outlook: Cognition Therapeutics estimates sufficient cash to fund operations and capital expenditures through the second quarter of 2027, ensuring financial stability that underpins the company's strategic growth plans.
See More
Cognition Therapeutics CEO to Present at Needham Conference
- Conference Presentation: Cognition Therapeutics' CEO Lisa Ricciardi is scheduled to present at the 25th Annual Needham Virtual Healthcare Conference on April 13 at 3:00 PM ET, where she will provide updates on the company's development programs for Alzheimer's disease and dementia with Lewy bodies, likely drawing investor interest.
- Clinical Research Progress: The company's investigational drug CT1812 (zervimesine) has shown promising efficacy signals in Phase 2 trials for dementia with Lewy bodies and mild-to-moderate Alzheimer's disease, with plans to advance it into late-stage clinical trials to address the urgent market need for effective treatments.
- Funding Support Background: Cognition Therapeutics has secured nearly $200 million in grants from the National Institutes of Health and related foundations to support its clinical research in neurodegenerative diseases, highlighting the company's strong R&D capabilities and market potential within the industry.
- Innovative Drug Development: As the company's lead candidate, CT1812 aims to help millions of families by developing novel and accessible therapies, reflecting the company's strategic vision and social responsibility in addressing neurodegenerative diseases.
See More
Cognition Therapeutics Advances CT1812 to Late-Stage Trials for DLB Psychosis
- Clinical Trial Progress: Cognition Therapeutics is advancing zervimesine (CT1812) into late-stage trials for dementia with Lewy bodies (DLB) psychosis, with an $80 million Phase 2 START trial readout expected in the second half of 2027, indicating significant progress in the treatment of neurodegenerative diseases.
- SHIMMER Trial Results: At the International Lewy Body Dementia Conference, zervimesine demonstrated a favorable impact across various symptom domains in the SHIMMER trial, particularly in neuropsychiatric assessments, highlighting its potential in the DLB psychosis market and possibly driving future demand.
- Commitment to Alzheimer's Disease: The Phase 2 SHINE study for mild-to-moderate Alzheimer's disease showed zervimesine achieving cognitive decline reductions comparable to approved monoclonal antibodies, especially in participants with low p-tau217 levels, indicating its therapeutic potential.
- START Study Funding Assurance: The START study has fully enrolled 545 participants with mild cognitive impairment and early Alzheimer's disease, funded by NIH grants, and is expected to provide critical data for the second half of 2027, further advancing zervimesine's clinical development.
See More
